Classical Hodgkin Lymphoma

Oncology·MeSH: Mastocytosis, Systemic

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

9 drugs in development·5 companies·5 clinical trials

Drug Pipeline by Phase

Phase 2(1)

Drug	Company
Ibrutinib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(2)

Drug	Company
gen3017	GENMAB A/S (GNMSF)
gen3017	Genmab A/S (GMAB)

Phase 4(6)

Drug	Company
Brentuximab Vedotin	Merus N.V. (MRUS)
Brentuximab Vedotin	PTC THERAPEUTICS, INC. (PTCT)
Dacarbazine	Merus N.V. (MRUS)
Vinblastine	Merus N.V. (MRUS)
Vinblastine	ENANTA PHARMACEUTICALS INC (ENTA)
Vinblastine	PTC THERAPEUTICS, INC. (PTCT)

BioSniper tracks 9 drugs in development for Classical Hodgkin Lymphoma across 5 companies.

There are 5 clinical trials targeting Classical Hodgkin Lymphoma tracked by BioSniper.

The estimated prevalence of Classical Hodgkin Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.